



PVDOMICS STUDY

Adjudication Committee Final Classification #701

This form documents the final decision of the Adjudication Committee for the case identified below.
A member of the DCC will complete the form on behalf of the Committee during discussion of the case.

--	--	--	--	--	--

1. Identification Number

--	--

2. Alphacode

--	--	--	--	--	--	--	--

3. Date of Final Adj Committee Review: mm/dd/yyyy

4. Identify PVD status of this participant.....
(1=*intentionally left blank*) 2=Comparator, complete Q5a-b; 3=PH, go to Q6.

a. What is the Primary WHO Group Comparator classification?

1=WHO Group 1

3=WHO Group 3

5=WHO Group 5

2=WHO Group 2

4=WHO Group 4

b. What is the Secondary WHO Group Comparator classification?

1=WHO Group 1

3=WHO Group 3

5=WHO Group 5

2=WHO Group 2

4=WHO Group 4

8=Not applicable

If Q4a-b were answered, skip to Q7 – Adjudication Committee rationale

5. What PH WHO Group does the Adjudication Committee think this participant falls into **now at time of final review**?

1=WHO Group 1

5=WHO Group 5

2=WHO Group 2

6=Mixed (*must complete Q5a-c, Q6-7*)

3=WHO Group 3

4=WHO Group 4

If response to **Q6 is 6=Mixed**, please identify WHO Groups using the codes below:

1=WHO Group 1

4=WHO Group 4

2=WHO Group 2

5=WHO Group 5

3=WHO Group 3

8=Not applicable

a. What is the Primary WHO Group classification?

b. What is the Secondary WHO Group classification?

c. What is the Tertiary WHO Group classification?

If Q5 **a and b** = WHO Groups 1 and/or 2 and/or 3, complete Q6:

Note: Participant can only be classified once in Q6a – e.

6. a. Is this participant's PH considered Mixed WHO Groups 2 & 3 as defined below (0=No, skip to 18c, 1=Yes).....

Definition:

•PCW > 18, LAH, LAE, atrial fib **AND**

•COPD, IPF, SSc-ILD, OHS, OSA, non-parenchymal restrictive lung diagnosis or CPFE

b. What is mixed WHO Group for 2 and 3? _____

1=WHO 2, 3: acute worsening in PCW with fluid challenge, exercise, pulmonary vasodilator

2=WHO 3, 2: acute worsening of oxygenation or only mild elevation of PCW

c. Is this participant's PH considered WHO 1 & 3 as described below (0=No, 1=Yes) _____

Features of WHO 1: i.e, autoimmune serology, positive family history **AND**

- mild (COPD, IPF, SSc-ILD, OHS, OSA, non-parenchymal restrictive lung diagnosis, CPFE);
ie. evidence of progressive PH in response to activity and/or over time with stability of hypoxemia or mild parenchymal lung disease

d. Is this participant's PH considered WHO 1, 2 as described below (0=No, 1=Yes) _____

WHO 1, 2: PAH (WHO 1, autoimmune serology) with provocation elevation in PCW

e. Is this participant's mixed PH described as 'other'? (0=No, 1=Yes) _____

If other, please describe and provide rationale in Comments below.

7. Adjudication Committee's Final Decision – Comments/Rationale:

200. Date the form completed..... _____ / _____ / _____

201. Username of Adjudication Committee Reviewer..... _____

(Username is the first 6 letters of physician's last name and first initial.)

Clinical Center Use Only

Date form entered (mm/dd/yyyy) _____ / _____ / _____

Username of person entering this form _____